Literature DB >> 17110097

The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent.

Jan P A Baak1, Paul J van Diest, Feja J Voorhorst, Elsken van der Wall, Louk V A M Beex, Jan B Vermorken, Emiel A M Janssen, Einar Gudlaugsson.   

Abstract

In lymph-node-negative invasive breast cancer patients<55 years, the proliferation marker mitotic activity index (MAI) has previously been shown to be the strongest prognosticator. In studies without age definition, MAI was not strongly prognostic. We investigated the age dependency of the prognostic value of proliferation for distant metastasis-free (MFS) and overall cancer-related survival (OS) in 1004 histologically diagnosed T1-3N0M0 invasive breast cancers (n=516, <55 years; n=322, 55-70 years; n=166, >70 years) without systemic adjuvant therapy and long follow-up (median: 108 months). The MAI decreases with age and the prognostic value of MAI varied by age group. For patients<55 years, hazard ratios (HR) for MAI>or=10 versus<10 for MFS and OS were 3.1 and 4.4, respectively (P<.0001 for both), but only 1.9 and 1.9 (P=.004 and .006) for patients aged 55-70 years, while over 70 years, MAI was not significant (P=.11). The prognostic value of proliferation was age-dependent. Prognostic breast cancer studies must clearly indicate the age group being studied.

Entities:  

Mesh:

Year:  2006        PMID: 17110097     DOI: 10.1016/j.ejca.2006.10.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  7 in total

1.  Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer.

Authors:  K Talvinen; J Tuikkala; O Nevalainen; A Rantanen; P Hirsimäki; J Sundström; P Kronqvist
Journal:  Br J Cancer       Date:  2008-07-01       Impact factor: 7.640

Review 2.  The Role of MicroRNAs as Predictors of Response to Tamoxifen Treatment in Breast Cancer Patients.

Authors:  Nina G Egeland; Siri Lunde; Kristin Jonsdottir; Tone H Lende; Deirdre Cronin-Fenton; Bjørnar Gilje; Emiel A M Janssen; Håvard Søiland
Journal:  Int J Mol Sci       Date:  2015-10-14       Impact factor: 5.923

3.  Assessment of tumour proliferation by use of the mitotic activity index, and Ki67 and phosphohistone H3 expression, in early-stage luminal breast cancer.

Authors:  Julia E C van Steenhoven; Anne Kuijer; Robert Kornegoor; Gijs van Leeuwen; Joost van Gorp; Thijs van Dalen; Paul J van Diest
Journal:  Histopathology       Date:  2020-08-30       Impact factor: 5.087

4.  Proliferative activity in Libyan breast cancer with comparison to European and Central African patients.

Authors:  Jamela Boder; Fathi Abdalla; Mohamed Elfagieh; Abdelbaset Buhmeida; Yrjö Collan
Journal:  Biomed Res Int       Date:  2013-09-11       Impact factor: 3.411

5.  Prognostic value of gene signatures and proliferation in lymph-node-negative breast cancer.

Authors:  Kristin Jonsdottir; Jörg Assmus; Aida Slewa; Einar Gudlaugsson; Ivar Skaland; Jan P A Baak; Emiel A M Janssen
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

6.  The prognostic value of mitotic activity index (MAI), phosphohistone H3 (PPH3), cyclin B1, cyclin A, and Ki67, alone and in combinations, in node-negative premenopausal breast cancer.

Authors:  Marie Klintman; Carina Strand; Cecilia Ahlin; Sanda Beglerbegovic; Marie-Louise Fjällskog; Dorthe Grabau; Einar Gudlaugsson; Emiel A M Janssen; Kristina Lövgren; Ivar Skaland; Pär-Ola Bendahl; Per Malmström; Jan P A Baak; Mårten Fernö
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240

7.  DTX3 copy number increase in breast cancer: a study of associations to molecular subtype, proliferation and prognosis.

Authors:  Marit Valla; Signe Opdahl; Borgny Ytterhus; Anna Mary Bofin
Journal:  Breast Cancer Res Treat       Date:  2021-02-22       Impact factor: 4.872

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.